Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › HURA

TuHURA Biosciences

HURA Lead: Phase 3 2 Biotech Distilled articles ↓ 31 filings & releases ↓ Cash $996K (Jun 30, 2026) ↓ 2 verdicts ↓
Oncology Nucleic AcidProtein

Market cap $104M 63.7M shares (10-Q, Aug 11, 2026) × $1.63 close Nov 6, 2026

Most recent annual filing: 2026-03-31

Catalyst timeline

11 trackedQuarter catalyst calendar →
  1. IFx-2.0 filing2H 2026IFx-2.0 filing, 2H 2026, notable
  2. TBS-2025 Ph1 start2H 2026TBS-2025 Ph1 start, 2H 2026, routine
  3. TBS-2025 / DOR ADC corporate2H 2026TBS-2025 / DOR ADC corporate, 2H 2026, routine
  4. HURA corporate updateNov 2026HURA corporate update, Nov 2026, routine
  5. TBS-2025 readout1H 2027TBS-2025 readout, 1H 2027, notable
  6. IFx-2.0 readout1H 2027IFx-2.0 readout, 1H 2027, notable
  7. HURA corporate manufacturing updateApr 21, 2027HURA corporate manufacturing update, Apr 21, 2027, routine
  8. IFx-2.0 Ph3 topline2H 2027IFx-2.0 Ph3 topline, 2H 2027, major
  9. HURA corporate financingDec 10, 2027HURA corporate financing, Dec 10, 2027, routine
  10. IFx-2.0 topline~Jan–Jul 2028IFx-2.0 topline, ~Jan–Jul 2028, thesis-defining
  11. HURA corporate financing~Feb–Apr 2028HURA corporate financing, ~Feb–Apr 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

Immune Fx

Innate immune agonist platform using plasmid DNA or mRNA to express immunogenic gram-positive bacterial protein (Emm55) on tumor cell surfaces, triggering innate immune recognition and overcoming primary resistance to checkpoint inhibitors; delivered via intratumoral injection (pDNA) or intravenous/autologous whole-cell administration (mRNA); focus: solid tumors and immuno-oncology

Targets: TLR-2

Delta Opioid Receptor

Delta Opioid Receptor (DOR) technology used to develop first-in-class bi-specific, bi-functional antibody drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells to inhibit immune-suppressing effects in the tumor microenvironment; focus area: prevention of T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies in AML

Targets: DOR, VISTA, Delta Opioid Receptor, MDSC

DOR

Delta Opioid Receptor (DOR) technology platform developing small molecule bi-specific/bi-functional ADCs targeting DOR on tumor-associated MDSCs to modulate immunosuppression in bone marrow and tumor microenvironment; focus area: oncology, acquired resistance to checkpoint inhibitors

Targets: DOR

Delta Opioid Receptor ADC

DOR antagonist-based bi-specific, bi-functional antibody drug conjugate technology targeting Delta Opioid Receptor (DOR) on Myeloid-Derived Suppressor Cells (MDSCs) to inhibit immunosuppression in the tumor microenvironment; also applicable to adoptive cellular immunotherapies (CAR-T, Treg, TIL); preclinical focus on blood-related cancers including AML and MDS

Targets: DOR

Discontinued (1)

Capital (as filed)

Cash
$996K cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$8.6M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.0M cash, runway into the end of 2028 per the deep dive of Oct 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on TuHURA Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-10-13 Avoid TuHURA Biosciences (HURA) - Scientific Deep Dive for IFx-2.0 (IFx-Hu2.0) and Pipeline Products IFx-2.0 showed only one PR in 21 patients on protocol, the 66% headline is a post-hoc rechallenge count reported five ways, the Phase 3 needs an ORR gain roughly twice the best add-on identified, and the balance sheet is a related-party revolver that runs out around the readout.
  2. 2026-10-27 Avoid UPDATE: TuHURA Biosciences (HURA) - Three for Three, Riding Shotgun Three PRs in three checkpoint-naive patients are consistent with Keytruda alone and carry no information about whether IFx-2.0 adds anything; none of the four watch-list triggers moved, and the Phase 3 binary and lender-constrained balance sheet are unchanged.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (31)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)